ProPhase Labs

• 1: Home
• 2: About Us
• 3: Business Units
  • 3.1: Cold-EEZE
  • 3.2: Quigley Pharma
  • 3.3: Quigley Manufacturing
  • 3.4: Phusion Laboratories
• 4: Investor Relations
  • 4.1: Annual Reports
  • 4.2: Review Our SEC Filings
  • 4.3: SEC Form 3, 4, & 5 Reporting
  • 4.4: Investor Kit Request
  • 4.6: Corporate Policies
• 5: News & Events
  • 5.1: ProPhase Labs News Releases
    • 5.1.1: Quigley Corporation Archived News
  • 5.2: Quigley Pharma News Releases
    • 5.2.1: Quigley Pharma Archived News Releases
• 6: Contact Us
• 8: Legal
  • 8.1: Privacy Policy
  • 8.2: Corporate Policies
• 16: Careers

Second Quarter Results Conference Call

The recorded conference call of 11:00 AM (EDT) Thursday August 12, 2010 is available here for replay until November 11, 2010.

The ProPhase Labs Approach

The Company’s approach to product development and marketing is to integrate nature and science to improve human health.

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA approved facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities, and a Pharma division, which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

ProPhase also owns 50% of Phusion Laboratories LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. The joint venture will formulate and test products to exploit market opportunities within ProPhase’s robust OTC distribution channels.

Our ongoing objective is to deliver long-term value to our stockholders by providing exceptional new products that address the health care and quality of life concerns of the broadest market segments

Business Units

	Cold-EEZE®More about Cold-EEZE®
	More about Phusion Laboratories, Inc.
	More about Quigley Pharma
	More about QMI